Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by enriquesuaveon Apr 27, 2021 12:49pm
179 Views
Post# 33074938

RE:RE:RE:Tertiary objectives.

RE:RE:RE:Tertiary objectives.It seems possible that either 13 or 14 or 15 was the patient who died as this patient showed negative urine cytology eliminating sign of cancer at 30 days, but unfortunately did not live long enough to get to 3 months exam. Just guessing here, as we only now learned of this outcome.
If this was the case it would have been 3 on 3.  Just a guess.
enriquesuave wrote: I wonder when will the partial responders be ruled out as either CR or not.  So far even at 6 months they are showing a negative cystoscope ( no visible cancer) but a positive urine cytology.  They have to use a uretoscope to examen for possible UTUC.   This is a very good sign that they are still showing no cancer with cystoscope after 6 months.  Numbers can go up dramatically if they are also deemed CR.  IMO. The numbers are showing the minimum possible CR rates which can only go up if those pending or partial responders become CR.  Add to that the second treatment which can possibly increase CR rates at 9 months and beyond.  

<< Previous
Bullboard Posts
Next >>